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Summary  There  is  paucity  of  data  on  the  incidence,  severity  and  management  of
chicken  pox  in  patients  receiving  active  chemotherapy  for  cancer.
From  October  2010  to  October  2011,  patients  were  included  in  this  study  if
they  developed  a  chicken  pox  infection  during  their  chemotherapy.  The  details  of
patients’  cancer  diagnosis  and  treatment  along  with  clinical  and  epidemiological
data  of  the  chicken  pox  infections  were  assessed  from  a  prospectively  maintained
database.
Twenty-four  patients  had  a  chicken  pox  infection  while  receiving  chemotherapy
and/or  radiotherapy.  The  median  age  of  the  patients  was  21  years,  and  two-thirds
of  the  patients  had  solid  tumor  malignancies.
Overall,  eight  (33%)  patients  had  complications,  six  (25%)  patients  had  febrile
neutropenia,  four  (17%)  had  diarrhea/mucositis,  and  four  (17%)  had  pneumonia.  The
median  time  for  recovery  of  the  infection  and  complications  in  the  patients  was  9.5
days  (5—29  days),  whereas  for  neutropenic  patients,  it  was  6.5  days  (3—14  days).  The
median  time  for  recovery  from  chicken  pox  infections  in  neutropenic  patients  was  10
days  (5—21  days),  compared  with  8.5  days  (0—29  days)  in  non-neutropenic  patients
(P  =  0.84).  The  median  time  for  recovery  from  infections  was  8.5  days  in  patients
with  comorbidities  (N  =  4),  which  was  the  same  for  patients  with  no  comorbidities.
The  clinical  presentation  and  complication  rates  of  chicken  pox  in  cancer  patients,
who  were  on  active  chemotherapy,  are  similar  to  the  normal  population.  The  recov-
ery  from  a  varicella  infection  and  complications  may  be  delayed  in  patients  with
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neutropenia.  The  varicella  infection  causes  a  therapy  delay  in  70%  of  patients.  Aggres-
sive  antiviral  therapy,  supportive  care  and  isolation  of  the  index  cases  remain  the
backbone  of  treatment.
©  2016  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
Limited.  All  rights  reserved.
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samples. A  P  value  of  <0.05  was  considered  sta-
tistically  signiﬁcant.  Recovery  from  neutropenia
was deﬁned  as  an  increase  in  the  absolute  neu-ntroduction
he  Varicella  Zoster  virus  (VZV)  is  categorized  as
n alfagroup  of  a  herpes  virus  family.  Chicken  pox  is
sually mild  and  associated  with  a  rapid  recovery  in
hildren. In  India,  children  often  acquire  the  infec-
ion at  an  early  age  and  develop  immunity  against
epeated  attacks  of  chicken  pox  [1,2].  Seventy-two
ercent of  the  population  between  the  ages  of  15
nd 25  years  will  have  developed  infections  and
eroconversion [1—3].
Immune  suppression  leads  to  severe,  prolonged
nd disseminated  chicken  pox  infections,  with
omplications,  including  pneumonia,  gastrointesti-
al, hepatic  involvement,  encephalitis  and  death
3,4].  Immune  suppression  in  malignancies  is  mul-
ifactorial  with  common  causes,  including  steroid
se, chemotherapy,  dysregulated  immunity  in
ematolymphoid  malignancies  and  bone  marrow
ransplantation  (BMT)  [4]. There  are  several  papers
n the  literature  on  herpes  zoster  and  chicken  pox
nfections  in  hematolymphoid  tumors,  especially  in
he BMT  settings  [4—6]. The  immune  suppression
n solid  tumor  malignancies  is  not  usually  severe  or
rolonged,  and  recovery  is  possible  within  2—5  days
uration.
Both chicken  pox  and  herpes  zoster  infections
ccur in  solid  tumor  patients;  there  is  however,  a
aucity of  data  on  prophylactic  acyclovir  and  vari-
ella vaccine  use,  as  well  as  a  lack  of  data  on  the
ncidence,  severity  and  treatment  of  chicken  pox
nfections in  patients  with  solid  tumor  malignancies
n active  chemotherapy.  Hence,  we  retrospectively
nalyzed our  database  to  assess  the  clinical  spec-
rum, severity,  complications  and  course  of  chicken
ox infections  in  patients  on  active  chemotherapy
nd to  explore  the  role  of  vaccination  and  acy-
lovir prophylaxis  in  relatives  of  patients  on  active
hemotherapy.
t
taterials and methods
etween  October  2010  and  October  2011,  we
etrospectively attempted  to  identify  all  of  the
atients  receiving  chemotherapy  from  the  depart-
ent  of  medical  oncology  who  developed  a chicken
ox infection  during  their  therapy.  BMT  patients
nd patients  with  herpes  zoster  infections  were
xcluded.
tatistical analysis
emographic  data  and  detailed  histories,  examina-
ions and  laboratory  parameters  noted  at  diagnosis
ere  recorded  and  assessed.  Demographic  data
ncluded  age,  gender,  Eastern  Cooperative  Oncol-
gy Group  performance  status,  comorbidities  such
s diabetes  mellitus,  the  type  of  malignancy  (solid
umors vs.  hematolymphoid  malignancy)  and  intent
f chemotherapy  and  laboratory  parameters  at  the
ime of  patients’  active  infections.  We  elicited  a
etailed history  of  chicken  pox  in  patients’  relatives
nd surrounding  people  and  a  personal  and  past  his-
ory of  chicken  pox.  The  laboratory  abnormalities
nd complications  at  diagnosis  were  graded  using
he common  terminology  criteria  for  adverse  events
CTCAE)  version  4.03.  The  potential  effect  of  vari-
us factors,  such  as  the  type  of  tumor  (i.e.,  solid  vs.
ematological  malignancy),  the  age  of  the  patient
adult vs.  pediatric)  and  the  presence  or  absence  of
omorbidities  on  the  duration  of neutropenia  and
uration  of  recovery  from  chicken  pox  infection
as calculated  with  Student’s  t-test  for  unpairedrophil count  (ANC)  ≥  1500  cmm−1. Recovery  from
he chicken  pox  infection  was  deﬁned  as  the  patient
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Table  1  Demographic  details.
Age  (n  =  24)  Median  21  years  Range  2—65  years
Gender  (n  =  24)  Males  15  (62%)  Female  9  (38%)
ECOG  PS  0—1  24(100%)  ≥2  0
Comorbidities  Yes  4  (16%)  No  20  (84%)
Past  history  of  chicken  pox  (available  in  13/24
patients)
Yes  3/13  (23%)  No  10/13  (67%)
History  of  chicken  pox  in  family/surrounding Yes 11/13(84%)  No  2/13(16%)
Table  2  Hematologic  parameters  at  the  time  of  vari-
cella  infection.
Parameters  Median  value  Range
Hb  10.95  gm/dl  (8.1—13.1)
WBC  5.20  ×  109 L—1 (0.3—12.1)
ANC  3.30  ×  109 L—1 (0.02—10.8)
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opeople  in  past  or  same  time  (available  in
13/24  patients)
being  afebrile  for  48  h  and  scabbing  of  the  chicken
pox rash.
Diagnosis of varicella infection (chicken
pox)
The  diagnosis  was  based  on  clinical  evaluation  of
the lesions,  speciﬁcally  classic  pleomorphic  lesions
at various  phases  of  eruption,  vesiculation  and
scabbing.  Clinical  photographs  were  used  for  docu-
menting  resolution  of  lesions.  Serology  was  not  used
for diagnosis  or  follow-up.  The  diagnosis  was  con-
ﬁrmed in  two  patients  with  the  DFA  method  on  the
scab scraping.  Remaining  cases  were  clinically  con-
ﬁrmed cases  with  an  epidemiological  association
with other  conﬁrmed  or  probable  cases.
Therapy and complications
We  assessed  the  therapy  administered  for  the
chicken  pox  infection  and  complications,  including
hospitalization,  ICU  admission,  myelosuppression
or organ  failure.  We  also  noted  any  delay  in  the
planned therapy,  including  chemotherapy  or  radio-
therapy  as  a  result  of  the  varicella  infection.
Results
Demographic details
During  the  one-year  period,  we  identiﬁed  24
patients  with  classical  chicken  pox  infection  while
on treatment,  including  chemotherapy  with  or
without  radiotherapy.  The  majority  of  them  were
adults (median  age  21  years),  and  two-thirds
of the  patients  had  solid  tumor  malignancies
receiving  curative  intent  neoadjuvant  or  adjuvant
chemotherapy  (Table  1).Cancer diagnosis and treatment details
Fifteen  (64%)  of  the  patients  were  adult  solid
tumor patients  (lung  cancer:  two,  breast  cancer:
C
E
tPlatelets  218  ×  10 L (6—587)
Albumin  3.4  gm/dl  (2.6—4.4)
ix,  sarcoma:  four,  others:  three);  ﬁve  patients
20%) were  adult  hematolymphoid  (NHL:  one,  acute
eukemia:  four)  and  four  (16%)  were  pediatric
atients (leukemia:  two,  non-Hodgkin’s  lymphoma:
ne,  sarcoma:  one).  All  patients  were  on  active
rst-line  chemotherapy  except  one  who  was  on  sec-
nd line  chemotherapy.  The  intent  of  chemother-
py was  curative  in  20  (83%)  patients.  Twenty
84%) patients  were  on  a  triplet  chemotherapy
egimen.
resenting symptoms
ll  patients  had  a pleomorphic  vesicular  rash  all
ver the  body,  especially  on  the  trunk,  which  was
iagnostic  of  chicken  pox  in  all  24  (100%)  patients.  A
igh grade  fever  was  observed  in  16  (66%)  patients.
ight patients  (33%)  had  gastrointestinal  symptoms,
n the  form  of  abdominal  pain,  diarrhea  or vomiting.
hree patients  (13%)  had  respiratory  complaints,
uch as  a  dry  cough  or  breathlessness.
ematologic parameters at the time of
aricella infection
welve  patients  (50%)  had  neutropenia  during  the
hicken pox  infection;  the  severity  was  grade  3  in
ne patient  and  grade  4  in  four  patients  (Table  2).omplications
ight  (33%)  patients  had  complications  during
he chicken  pox  infections.  Six  patients  (25%)
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Table  3  Comparison  between  recovery  from  infection  and  neutropenia  in  patients  with  solid  tumors  vs.  hema-
tolymphoid  and  adult  vs.  pediatric  patients.
Median  duration  in  days  Solid  tumors  Hematolymphoid  malignancies  P  value
For  recovery  from  the  infections  8.5  (3—21)  N  =  16  8.5  (6—29)  N  =  8  P  =  0.34
Recovery  from  the  neutropenia  7  (3—10)  N  =  8  7  (6—14)  N  =  3  P  =  0.42
Median  duration  in  days  Adult  patients  Pediatric  patients  P  value
For  recovery  from  the  infections 8  (3—21)  N  =  17 10  (5—29)  N  =  7 P =  0.45
 N  =  7
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dRecovery  from  the  neutropenia 7  (3—10)
ad  febrile  neutropenia;  four  (17%)  had  diar-
hea/mucositis; and  four  patients  (17%)  had
neumonia,  of  which  three  were  bacterial  (consol-
dation with  air  bronchogram)  and  one  was  fungal
neumonia  (ﬁbronodular  lesions  with  ground  glass
pacities)  based  on  a  CT  of  the  thorax.  One  patient
ad central  nervous  system  involvement  in  the  form
f convulsions,  which  were  not  related  to  high  grade
ever. He  had  developed  intraparenchymal  hemor-
hage  along  with  grade  3  myelosuppression  required
CU admission,  ionotropic  support  for  hypotension,
long with  antifungals  and  third  line  antibiotics.
one of  the  patients  died  of  the  complications
elated to  their  varicella  infections.
herapy for the varicella infection
ntravenous  acyclovir  was  administered  to  19  (79%)
atients,  and  ﬁve  (21%)  patients  were  managed
ith oral  acyclovir.  The  acyclovir  course  consisted
f 14  days  of  the  therapeutic  dose  of  10  mg/kg/dose
dministered three  times  a  day,  followed  by  oral
econdary  prophylaxis  until  the  completion  of
hemotherapy.  Admissions  were  required  for  20
84%) patients  with  isolation  in  an  attempt  to  pre-
ent the  spread  of  the  infection  to  the  other
atients in  the  hospital.  Eight  patients  were  given
rowth  factor  support  as  a  part  of managing  the
ebrile  or  non-febrile  neutropenia.
linical course and recovery
he  median  time  for  recovery  of  the  infection
nd its  complications  in  all  patients  was  9.5  days
5—29 days),  whereas  neutropenic  patients  recov-
red with  a  median  duration  of  6.5  days  (3—14
ays). The  median  time  for  recovery  from  chicken
ox infections  in  neutropenic  patients  was  10  days
5—21 days),  compared  with  8.5  days  (0—29  days)
n non-neutropenic  patients  (P  =  0.84).  The  median
ime for  recovery  from  infections  was  8.5  days
n patients  with  comorbidities,  which  was  the
ame for  patients  without  any  comorbidities.  The
omparison  between  recovery  from  infection  and
n
t
t
w7 (4—14)  N  =  5 P  =  0.66
ecovery  from  neutropenia  in  patients  with  solid
umors  compared  with  hematolymphoid  malignan-
ies and  adult  vs.  pediatric  patients  is  shown  in
able  3.
ffect of chicken pox on cancer-related
herapy
aricella  infection  caused  a  delay  or  omission  of
hemotherapy  in  17  (70%)  patients  and  in  radio-
herapy  treatment  of  three  (12.5%)  patients.  The
edian number  of  days  of  delay  for  chemother-
py or  radiotherapy  treatment  was  nine  days  (0—51
ays).
iscussion
n  India,  most  children  are  exposed  to  a varicella
nfection during  early  childhood  [8]. Past  clinical
r subclinical  infections  demonstrated  by  a raised
ntibody  level  in  the  serum,  provides  protection
rom future  chicken  pox  infections  during  periods  of
mmunosuppression  [8].  Treating  a varicella  infec-
ion and  its  complications  in  pediatric  patients  with
eukemia and  those  undergoing  BMT  is a  standard
ractice based  on  the  recommended  guidelines  [9].
n regard  to  chicken  pox  in  adult  solid  tumor  malig-
ancies,  there  are  many  questions  that  remain
nanswered.
We report  on  24  patients  with  chicken  pox  infec-
ions during  active  chemotherapy.  The  majority  of
he patients  were  adult  patients  with  solid  tumor
alignancies  and  our  results  give  some  insight  into
his disease  and  its  impact  on  the  treatment  of
ancer.  Our  results  also  highlight  many  important
spects of  chicken  pox  infections  in  solid  tumor
alignancies, which  is  scarce  in  the  literature.
The clinical  presentation  in  oncology  patients
id not  seem  to  differ  from  those  without  malig-
ancies. The  complication  rates  were  comparable
o pediatric  malignancies,  such  as  pneumonia,
hat occurred  in  16.5%  in  our  cohort  compared
ith 15—27%  that  was  previously  reported  in
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pediatric  malignancies  [4]. There  were  no  mor-
talities  attributable  to  chicken  pox  infection,
suggesting that  aggressive  antiviral  therapy  and
supportive  care  are  essential  components  for  man-
aging these  patients.
The  severity  of  disease  or  delay  in  recovery  from
the disease  was  not  signiﬁcantly  different  in  any
particular  chemotherapy  protocol,  and  the  same
is also  true  for  hematological  malignancy  vs.  solid
tumor cancers.  However,  this  may  be  due  to  the
small  numbers  in  our  study.
Various  factors  such  as  the  presence  of  comor-
bidities, neutropenia,  type  of  malignancy  (solid  vs.
hematolymphoid)  and  the  age  of  the  patient  (adult
vs. pediatric)  did  not  appear  to  have  any  signiﬁ-
cant effect  on  the  time  taken  to  recover  from  a
varicella  infection.  Although  the  median  duration
of neutropenia  was  the  same  in  adults  vs.  pedi-
atric patients,  the  median  duration  of  recovery
from varicella  infection  was  numerically  longer  in
pediatric  patients  compared  with  adults  and  in  neu-
tropenic patients  compared  with  patients  without
neutropenia;  however,  these  variables  did  not  reach
statistical  signiﬁcance.  The  small  numbers  in  this
study preclude  any  ﬁrm  comment  on  these  factors
being  signiﬁcant.
We found  that  70%  of  our  patients  had  a delay
(median of  nine  days)  in  chemotherapy  as  a  result
of varicella  infection.  Eighty-three  percent  of  our
patients were  receiving  therapy  with  the  intent  to
cure. It  is  widely  known  that  delays  in  curative
treatment  can  lead  to  an  inferior  outcome,  as  has
been studied  extensively  in  breast  cancer  patients
[10].  There  is  a  clear  need  to  prevent  chicken  pox
infections  effectively  in  cancer  patients  on  active
chemotherapy  to  ensure  that  these  patients  have
the best  possible  outcome  from  therapy.
In our  cohort,  84%  patients  had  a  past  recent
history of  exposure  to  active  chicken  pox  infec-
tion, with  three  of  the  patients  staying  in  close
proximity to  each  other.  Only  two  of  these  13  had
developed  childhood  clinical  chicken  pox  infection,
while the  remaining  patients  probably  were  unex-
posed  to the  varicella  virus.  Of  note,  there  was
no documented  epidemic  of  chicken  pox  in  Mum-
bai during  the  period  of  our  analysis.  None  of  the
patients’  relatives  had  received  varicella  vaccines
and  no  patient  was  offered  prophylactic  acyclovir
after the  diagnosis  of  chicken  pox  in  the  relatives.
As a  result  of  an  overall  improvement  in  socio-
economic status,  the  age  of  exposure  to  varicella
infections in  Indian  patients  is  shifting  to  the  adult
age. The  varicella  infection  in  an  adult  is much
more severe  compared  with  childhood  varicella
infections. This  fact,  combined  with  the  immuno-
suppression due  to  chemotherapy  for  malignancies,
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robably  contributed  to  the  complications  and  ther-
py delays  in  our  patients.  We  need  to  consider
mplementing a  vaccination  program  for  relatives,
ven  in  adult  solid  tumor  cancer  patients.  There  are
any recommendations  for  sibling  vaccinations  and
hild vaccination  during  the  maintenance  therapy
n ALL  [11,12], which  needs  additional  consider-
tion in  adult  solid  tumor  malignancies.
The safety  of  the  chicken  pox  vaccine  in  chil-
ren with  hematological  malignancies,  who  are  on
ctive chemotherapy,  is  controversial  [13,14].  Non-
mmune children  with  cancer  can  be  effectively
accinated against  chicken  pox  during  the  mainte-
ance phase  of  their  acute  leukemia  treatment  or
pproximately  three  to  six  months  from  treatment
iscontinuation  in  those  with  solid  tumors  [15].  In
linical trials,  transmission  of  the  vaccination  ver-
ion of  the  virus  to  immune-compromised  contacts
rom vaccine  recipients  is  not  reported,  but  a  pos-
ible transmission  can  occur  rarely  from  vaccine
ecipients who  develop  a varicella-like  rash  [16].
Isolation  is  another  major  tool  in  preventing
he spread  of  infection.  We  used  isolation  for  the
npatient  management  of  the  active  chicken  pox
atients;  this  strategy  likely  helped  in  preventing
he spread  and  possible  chicken  pox  outbreak  in
ur center,  which  caters  to  approximately  54,000
ancer  patients  per  year.  Isolation  of  an  actively
nfected chicken  pox  patient  in  a  negative  pressure
oom  is  recommended  by  the  American  Academy  of
ediatrics [17]. If  negative  air-ﬂow  rooms  are  not
vailable,  patients  with  varicella  should  be  isolated
n closed  rooms  and  have  no  contact  with  persons
ithout evidence  of  varicella  immunity;  patients
hould only  be  cared  for  by  staff  with  varicella
mmunity. Pediatric  oncology  units  have  begun  to
mplement isolation  measures  after  the  emergence
f reports  of  chicken  pox  infection  outbreaks  in
ards [18].
To  summarize,  the  clinical  presentation  and
omplication rates  of  chicken  pox  in  cancer  patients
ho were  on  active  chemotherapy  are  similar  to
he normal  population.  The  recovery  from  a  vari-
ella infection  and  complications  may  be  delayed  in
atients with  neutropenia.  The  varicella  infection
auses  a therapy  delay  in  70%  of  patients.  Aggres-
ive antiviral  therapy,  supportive  care  and  isolation
f the  index  cases  remain  the  backbone  of  treat-
ent.
Our data  had  a small  number  of  patients  and  was
 retrospective  analysis.  Patients  were  randomly
elected and  the  patient  group  was  heterogeneous,
ncluding both  adult  and  pediatric  patients  with
olid tumors  or  hematolymphoid  malignancies.  A
trength of  our  analysis  includes  the  fact  that
t describes  the  complications  of  a chicken  pox
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nfection  in  patients  with  malignancies  receiving
ctive therapy.  It  also  discusses  the  differential
ffects of  neutropenia,  tumor  type,  age  of  patients
nd  the  presence  of  comorbidities  on  the  patients’
bility to  recover  from  a  chicken  pox  infection.  This
aper describes  the  delays  in  chemotherapy  and
adiotherapy  treatment  due  to  a  varicella  infec-
ion.  Most  importantly,  the  inclusion  of  adult  solid
umor patients  and  the  descriptions  of  their  clini-
al courses  and  complications  when  they  develop  a
aricella infection  while  on  active  anti-tumor  ther-
py is  unique.
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